FIELD: medicine. SUBSTANCE: method involves administering Galavita preparation belonging to phthalhydrazide group at a dose of 25-1000 mg as injections done under known schedule in combination with curative ointments based on Mylife preparation and per os administering the Mylife preparation. EFFECT: enhanced effectiveness of treatment; accelerated treatment course.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING FIBROCYSTIC DISEASE IN GYNAECOLOGIC PATIENTS | 2009 |
|
RU2405598C2 |
| METHOD AND INTRACAVITARY END PIECE FOR TREATING THE PATIENT FOR UTERINE MYOMA AGGRAVATED WITH FIBROUS CYST DISEASE OF THE MAMMARY GLANDS | 2000 |
|
RU2200599C2 |
| IMMUNOMODULATING AGENT | 1997 |
|
RU2113222C1 |
| METHOD OF TREATING THYROID GLAND HYPOFUNCTION | 1998 |
|
RU2132188C1 |
| METHOD FOR CORRECTING HORMONAL AND IMMUNE DISORDERS IN PATIENTS WITH HORMONODEPENDENT DISEASES | 2004 |
|
RU2281748C2 |
| METHOD FOR TREATING UTERINE MYOMA IN COMBINATION WITH MASTOPATHY | 2002 |
|
RU2257921C2 |
| METHOD OF TREATING BENIGN HYPERPLASTIC PROCESSES OF FEMALE REPRODUCTIVE SYSTEM | 2011 |
|
RU2471485C1 |
| METHOD FOR TREATING CHILDREN FOR AUTOIMMUNE THYROIDITIS | 2002 |
|
RU2221535C1 |
| METHOD FOR TREATING PATIENTS WITH HORMONALLY DEPENDENT DISEASES | 2005 |
|
RU2297823C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ENDOMETRIOSIS AND METHOD FOR PREPARATION THEREOF | 2014 |
|
RU2582965C2 |
